Mankind is trying to combat the pandemic with various medication and vaccine trials. Although there are numerous trials in place, one of them is proven to be successful. While we are still waiting to get a successful vaccine, a new investigation seems promising. According to the National Institute of Health (NIH), a dose of ChAdOx1 nCoV-19 is able to protect six rhesus macaque from COVID-19 pneumonia.
The vaccine, developed by the Jenner Institute, Oxford University, began its Phase 1 trial. The vaccine is said to based on the application deficient chimpanzee adenovirus that confers immunity against the SARS-CoV-2. In the trial, six animals from the National Institute of Allergy and Infectious Diseases received the vaccine. They were then experimentally infected with SARS-CoV-2 twenty-eight days later, and their results were compared with three control animals.
The results show us that vaccinated animals show no signs of disease and lung damage when compared to unvaccinated animals. However, we should see that ChAdOx1 is not the first time used as a vaccine. Reports suggest that it has already been used against MERS-CoV. Therefore, these vaccines have every chance that they can be used against the SARS-CoV-2. With more than 100 candidates around the globe trying to combat the virus, we do not have a confirmatory result yet. With promising results in the future, we can definitely hope this candidate becomes a possible vaccine. With future studies and larger trials, we can hope we find a way to fight the disease.
Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!
Source: Fox News